Skip to main content
Clinical Trials/NCT05163951
NCT05163951
Recruiting
Not Applicable

Effectiveness and Safety of Trabeculectomy and Peripheral Iridectomy Plus Goniotomy in Advanced Primary Angle-closure Glaucoma: a Multicenter Non-inferiority Randomized Controlled Trial

Sun Yat-sen University1 site in 1 country88 target enrollmentJanuary 5, 2022

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Primary Angle Closure Glaucoma
Sponsor
Sun Yat-sen University
Enrollment
88
Locations
1
Primary Endpoint
Intraocular pressure at postoperative 12 months
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

A multicenter, parallel, open, non-inferior randomized controlled trial is conducted to compare the effectiveness and safety of trabeculectomy and peripheral iridectomy plus goniotomy (TVG) in the treatment of advanced primary angle closure glaucoma with no or mild cataracts.

Detailed Description

Primary angle-closure glaucoma (PACG) has a high prevalence and blinding rate in China. The routine first-line treatment of advanced PACG is trabeculectomy, especially in those without cataract. However, due to surgery complications and exhausting post-surgery caring, traditional trabeculectomy is not an ideal choice in clinical practice, particularly in patients with high risk of complications such as younger age and shorter axial length. Peripheral iridectomy (SPI) plus intraocular pressure (IOP)-lowering medications is an alternative. Minimally invasive glaucoma surgery (MIGS) has recently showed its safety and effectiveness in the treatment of PACG, usually combined with cataract surgery, goniosynechialysis (GSL) and goniotomy(GT). The safety and effectiveness of phacoemulsification and intraocular lens implantation (PEI)+GSL+GT in advanced PACG with cataract has been conducted (clinical trials.gov, NCT04878458). It is valuable to explore the safety and efficacy of SPI+GSL+GT in these PACG patients with no or mild cataracts. Therefore, this study intends to conduct a multicenter, non-inferior randomized controlled clinical trial to compare the effectiveness and safety of trabeculectomy versus SPI+GSL+GT in advanced PACG with no or mild cataracts.

Registry
clinicaltrials.gov
Start Date
January 5, 2022
End Date
June 30, 2026
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Sun Yat-sen University
Responsible Party
Principal Investigator
Principal Investigator

Xiulan Zhang

Director of Clinical Research Center

Sun Yat-sen University

Eligibility Criteria

Inclusion Criteria

  • Age 45-80 years.
  • Eyes diagnosed with advanced PACG who meet following criteria a, b, and c; or a, b, and d:
  • PAS: ≥180° range, including nasal and inferior quadrants;
  • IOP \>21 mmHg with or without anti-glaucoma medications (the medications include the maximally tolerated medications), taken with the Goldmann applanation tonometer;
  • Glaucomatous optic neuropathy (cup-to-disc \[C/D\] ratio ≥0.7, C/D asymmetry \>0.2, or rim width at the superior and inferior temporal areas \<0.1 of the vertical diameters of the optic disc);
  • Glaucomatous visual field defects (nasal step, arcuate scotoma, and paracentral scotoma on a reliable Humphrey analyzer and a mean deviation of ≤-12 dB).
  • No or mild cataracts and uncorrected visual acuity of ≥0.63 (Early Treatment Diabetic Retinopathy Study chart);
  • Axial length of ≥20 mm.

Exclusion Criteria

  • History of ocular surgery or trauma.
  • Retinal disease that influences the collection of ocular parameters or other types of glaucoma, including open-angle glaucoma, secondary angle-closure glaucoma, steroidal glaucoma, angle recession glaucoma, neovascular glaucoma, nanophthalmos, and pseudoexfoliation syndrome.
  • Monophthalmia (best-corrected visual acuity of \<0.01 in the non-study eye).
  • An International Standardized Ratio of \>3.0, for patients receiving warfarin or anticoagulant therapy before surgery.
  • Patients with serious systemic diseases.
  • Pregnant or lactating women.
  • If both eyes are eligible for the study, the eye with the worse visual field or optic nerve will be included.

Outcomes

Primary Outcomes

Intraocular pressure at postoperative 12 months

Time Frame: Postoperative 12 month

Intraocular pressure after surgery using Goldmann or non-contact tonometer.

Secondary Outcomes

  • Cumulative success rate of surgery(Postoperative 12, 24, 36 months)
  • The numbers of anti-glaucoma medications(Postoperative 0, 1, 7 days, and 1, 3, 6, 12, 18, 24, 30, 36 months)
  • Intraoperative and postoperative complications(Postoperative 0, 1, 7 days, and 1, 3, 6, 12, 18, 24, 30, 36 months)

Study Sites (1)

Loading locations...

Similar Trials